Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 25 entries
Sorted by: Best Match Show Resources per page
Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype.

JCI insight

Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, Thomas G, Zhou S, Wang Q, Elakkad A, Liebelt BD, Yaghi NK, Ezhilarasan R, Huang N, Weinberg JS, Prabhu SS, Rao G, Sawaya R, Langford LA, Bruner JM, Fuller GN, Bar-Or A, Li W, Colen RR, Curran MA, Bhat KP, Antel JP, Cooper LJ, Sulman EP, Heimberger AB.
PMID: 26973881
JCI Insight. 2016;1(2). doi: 10.1172/jci.insight.85841. Epub 2016 Feb 25.

Glioblastomas are highly infiltrated by diverse immune cells, including microglia, macrophages, and myeloid-derived suppressor cells (MDSCs). Understanding the mechanisms by which glioblastoma-associated myeloid cells (GAMs) undergo metamorphosis into tumor-supportive cells, characterizing the heterogeneity of immune cell phenotypes within glioblastoma...

Cite
Gabrusiewicz K, Rodriguez B, Wei J, et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 2016;1(2)doi: 10.1172/jci.insight.85841.
Gabrusiewicz, K., Rodriguez, B., Wei, J., Hashimoto, Y., Healy, L. M., Maiti, S. N., Thomas, G., Zhou, S., Wang, Q., Elakkad, A., Liebelt, B. D., Yaghi, N. K., Ezhilarasan, R., Huang, N., Weinberg, J. S., Prabhu, S. S., Rao, G., Sawaya, R., Langford, L. A., Bruner, J. M., Fuller, G. N., Bar-Or, A., Li, W., Colen, R. R., Curran, M. A., Bhat, K. P., Antel, J. P., Cooper, L. J., Sulman, E. P., & Heimberger, A. B. (2016). Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI insight, 1(2), . https://doi.org/10.1172/jci.insight.85841
Gabrusiewicz, Konrad, et al. "Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype." JCI insight vol. 1,2 (2016). doi: https://doi.org/10.1172/jci.insight.85841
Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, Thomas G, Zhou S, Wang Q, Elakkad A, Liebelt BD, Yaghi NK, Ezhilarasan R, Huang N, Weinberg JS, Prabhu SS, Rao G, Sawaya R, Langford LA, Bruner JM, Fuller GN, Bar-Or A, Li W, Colen RR, Curran MA, Bhat KP, Antel JP, Cooper LJ, Sulman EP, Heimberger AB. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 2016;1(2). doi: 10.1172/jci.insight.85841. Epub 2016 Feb 25. PMID: 26973881; PMCID: PMC4784261.
Copy Download .nbib Format: NLM
An updated h-index measures both the primary and total scientific output of a researcher.

Discoveries (Craiova, Romania)

Bucur O, Almasan A, Zubarev R, Friedman M, Nicolson GL, Sumazin P, Leabu M, Nikolajczyk BS, Avram D, Kunej T, Calin GA, Godwin AK, Adami HO, Zaphiropoulos PG, Richardson DR, Schmitt-Ulms G, Westerblad H, Keniry M, Grau GE, Carbonetto S, Stan RV, Popa-Wagner A, Takhar K, Baron BW, Galardy PJ, Yang F, Data D, Fadare O, Yeo KJ, Gabreanu GR, Andrei S, Soare GR, Nelson MA, Liehn EA.
PMID: 26504901
Discoveries (Craiova). 2015 Jul-Sep;3(3). doi: 10.15190/d.2015.42. Epub 2015 Sep 30.

The growing interest in scientometry stems from ethical concerns related to the proper evaluation of scientific contributions of an author working in a hard science. In the absence of a consensus, institutions may use arbitrary methods for evaluating scientists...

Cite
Bucur O, Almasan A, Zubarev R, et al. An updated h-index measures both the primary and total scientific output of a researcher. Discoveries (Craiova). 2015;3(3)doi: 10.15190/d.2015.42.
Bucur, O., Almasan, A., Zubarev, R., Friedman, M., Nicolson, G. L., Sumazin, P., Leabu, M., Nikolajczyk, B. S., Avram, D., Kunej, T., Calin, G. A., Godwin, A. K., Adami, H. O., Zaphiropoulos, P. G., Richardson, D. R., Schmitt-Ulms, G., Westerblad, H., Keniry, M., Grau, G. E., Carbonetto, S., Stan, R. V., Popa-Wagner, A., Takhar, K., Baron, B. W., Galardy, P. J., Yang, F., Data, D., Fadare, O., Yeo, K. J., Gabreanu, G. R., Andrei, S., Soare, G. R., Nelson, M. A., & Liehn, E. A. (2015). An updated h-index measures both the primary and total scientific output of a researcher. Discoveries (Craiova, Romania), 3(3), . https://doi.org/10.15190/d.2015.42
Bucur, Octavian, et al. "An updated h-index measures both the primary and total scientific output of a researcher." Discoveries (Craiova, Romania) vol. 3,3 (2015). doi: https://doi.org/10.15190/d.2015.42
Bucur O, Almasan A, Zubarev R, Friedman M, Nicolson GL, Sumazin P, Leabu M, Nikolajczyk BS, Avram D, Kunej T, Calin GA, Godwin AK, Adami HO, Zaphiropoulos PG, Richardson DR, Schmitt-Ulms G, Westerblad H, Keniry M, Grau GE, Carbonetto S, Stan RV, Popa-Wagner A, Takhar K, Baron BW, Galardy PJ, Yang F, Data D, Fadare O, Yeo KJ, Gabreanu GR, Andrei S, Soare GR, Nelson MA, Liehn EA. An updated h-index measures both the primary and total scientific output of a researcher. Discoveries (Craiova). 2015 Jul-Sep;3(3). doi: 10.15190/d.2015.42. Epub 2015 Sep 30. PMID: 26504901; PMCID: PMC4617786.
Copy Download .nbib Format: NLM
miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma.

Clinical investigation

Jethwa K, Wei J, McEnery K, Heimberger AB.
PMID: 22468222
Clin Investig (Lond). 2011 Dec;1(12):1637-1650. doi: 10.4155/cli.11.159.

Glioblastoma (GB), the most common primary neoplasm of the CNS, remains universally fatal with standard therapies and has a mean overall survival time of only 14.6 months. Even in the most favorable situations most patients do not survive longer...

Cite
Jethwa K, Wei J, McEnery K, et al. miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma. Clin Investig (Lond). 2011;1(12):1637-1650doi: 10.4155/cli.11.159.
Jethwa, K., Wei, J., McEnery, K., & Heimberger, A. B. (2011). miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma. Clinical investigation, 1(12), 1637-1650. https://doi.org/10.4155/cli.11.159
Jethwa, Krishan, et al. "miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma." Clinical investigation vol. 1,12 (2011): 1637-1650. doi: https://doi.org/10.4155/cli.11.159
Jethwa K, Wei J, McEnery K, Heimberger AB. miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma. Clin Investig (Lond). 2011 Dec;1(12):1637-1650. doi: 10.4155/cli.11.159. PMID: 22468222; PMCID: PMC3314429.
Copy Download .nbib Format: NLM
Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis.

Translational lung cancer research

Chakravarti N, Prieto VG.
PMID: 26798583
Transl Lung Cancer Res. 2015 Dec;4(6):743-51. doi: 10.3978/j.issn.2218-6751.2015.12.10.

Anti-programmed death-1 (anti-PD1)/programmed death ligand-1 (PD-L1) therapeutic antibodies targeting regulatory pathways in T cells have recently shown to promising clinical effectiveness in several solid tumors by enhancing antitumor immune response. Immune checkpoint therapy has propelled therapeutic efforts opening a...

Cite
Chakravarti N, Prieto VG. Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. Transl Lung Cancer Res. 2015;4(6):743-51doi: 10.3978/j.issn.2218-6751.2015.12.10.
Chakravarti, N., & Prieto, V. G. (2015). Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. Translational lung cancer research, 4(6), 743-51. https://doi.org/10.3978/j.issn.2218-6751.2015.12.10
Chakravarti, Nitin, and Prieto, Victor G. "Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis." Translational lung cancer research vol. 4,6 (2015): 743-51. doi: https://doi.org/10.3978/j.issn.2218-6751.2015.12.10
Chakravarti N, Prieto VG. Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. Transl Lung Cancer Res. 2015 Dec;4(6):743-51. doi: 10.3978/j.issn.2218-6751.2015.12.10. PMID: 26798583; PMCID: PMC4700222.
Copy Download .nbib Format: NLM
Novel genetic variants of .

American journal of cancer research

Lu G, Zhou B, He Y, Liu H, Luo S, Amos CI, Lee JE, Yang K, Qureshi A, Han J, Wei Q.
PMID: 33163277
Am J Cancer Res. 2020 Oct 01;10(10):3382-3394. eCollection 2020.

Endosomes regulate cell polarity, adhesion, signaling, immunity, and tumor progression, which may influence cancer outcomes. Here we evaluated associations between 36,068 genetic variants of 228 endosome-related pathway genes and cutaneous melanoma disease-specific survival (CMSS) using genotyping data from two...

Cite
Lu G, Zhou B, He Y, et al. Novel genetic variants of . Am J Cancer Res. 2020;10(10):3382-3394
Lu, G., Zhou, B., He, Y., Liu, H., Luo, S., Amos, C. I., Lee, J. E., Yang, K., Qureshi, A., Han, J., & Wei, Q. (2020). Novel genetic variants of . American journal of cancer research, 10(10), 3382-3394.
Lu, Guiqing, et al. "Novel genetic variants of ." American journal of cancer research vol. 10,10 (2020): 3382-3394.
Lu G, Zhou B, He Y, Liu H, Luo S, Amos CI, Lee JE, Yang K, Qureshi A, Han J, Wei Q. Novel genetic variants of . Am J Cancer Res. 2020 Oct 01;10(10):3382-3394. eCollection 2020. PMID: 33163277; PMCID: PMC7642651.
Copy Download .nbib Format: NLM
Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy.

Clinical cancer research : an official journal of the American Association for Cancer Research

Ott M, Kassab C, Marisetty A, Hashimoto Y, Wei J, Zamler D, Leu JS, Tomaszowski KH, Sabbagh A, Fang D, Gupta P, Priebe W, Zielinski RJ, Burks JK, Long JP, Kong LY, Fuller GN, DeGroot J, Sulman EP, Heimberger AB.
PMID: 32605912
Clin Cancer Res. 2020 Sep 15;26(18):4983-4994. doi: 10.1158/1078-0432.CCR-19-4092. Epub 2020 Jun 30.

PURPOSE: Patients with central nervous system (CNS) tumors are typically treated with radiotherapy, but this is not curative and results in the upregulation of phosphorylated STAT3 (p-STAT3), which drives invasion, angiogenesis, and immune suppression. Therefore, we investigated the combined...

Cite
Ott M, Kassab C, Marisetty A, et al. Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy. Clin Cancer Res. 2020;26(18):4983-4994doi: 10.1158/1078-0432.CCR-19-4092.
Ott, M., Kassab, C., Marisetty, A., Hashimoto, Y., Wei, J., Zamler, D., Leu, J. S., Tomaszowski, K. H., Sabbagh, A., Fang, D., Gupta, P., Priebe, W., Zielinski, R. J., Burks, J. K., Long, J. P., Kong, L. Y., Fuller, G. N., DeGroot, J., Sulman, E. P., & Heimberger, A. B. (2020). Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(18), 4983-4994. https://doi.org/10.1158/1078-0432.CCR-19-4092
Ott, Martina, et al. "Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 26,18 (2020): 4983-4994. doi: https://doi.org/10.1158/1078-0432.CCR-19-4092
Ott M, Kassab C, Marisetty A, Hashimoto Y, Wei J, Zamler D, Leu JS, Tomaszowski KH, Sabbagh A, Fang D, Gupta P, Priebe W, Zielinski RJ, Burks JK, Long JP, Kong LY, Fuller GN, DeGroot J, Sulman EP, Heimberger AB. Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy. Clin Cancer Res. 2020 Sep 15;26(18):4983-4994. doi: 10.1158/1078-0432.CCR-19-4092. Epub 2020 Jun 30. PMID: 32605912.
Copy Download .nbib Format: NLM
Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas.

JCO precision oncology

Kwong LN, De Macedo MP, Haydu L, Joon AY, Tetzlaff MT, Calderone TL, Wu CJ, Kwong MK, Roszik J, Hess KR, Davies MA, Lazar AJ, Gershenwald JE.
PMID: 31058252
JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00259. Epub 2018 Jun 14.

PURPOSE: Initiatives such as The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) have generated high-quality, multi-platform molecular data from thousands of frozen tumor samples. While these initiatives have provided invaluable insight into cancer biology, a tremendous...

Cite
Kwong LN, De Macedo MP, Haydu L, et al. Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas. JCO Precis Oncol. 2018;2018doi: 10.1200/PO.17.00259.
Kwong, L. N., De Macedo, M. P., Haydu, L., Joon, A. Y., Tetzlaff, M. T., Calderone, T. L., Wu, C. J., Kwong, M. K., Roszik, J., Hess, K. R., Davies, M. A., Lazar, A. J., & Gershenwald, J. E. (2018). Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas. JCO precision oncology, 2018. https://doi.org/10.1200/PO.17.00259
Kwong, Lawrence N, et al. "Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas." JCO precision oncology vol. 2018 (2018). doi: https://doi.org/10.1200/PO.17.00259
Kwong LN, De Macedo MP, Haydu L, Joon AY, Tetzlaff MT, Calderone TL, Wu CJ, Kwong MK, Roszik J, Hess KR, Davies MA, Lazar AJ, Gershenwald JE. Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas. JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00259. Epub 2018 Jun 14. PMID: 31058252; PMCID: PMC6498859.
Copy Download .nbib Format: NLM
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research

Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE.
PMID: 19996208
Clin Cancer Res. 2009 Dec 15;15(24):7538-7546. doi: 10.1158/1078-0432.CCR-09-1985.

PURPOSE: Activation of the phosphoinositide 3-kinase (PI3K)-AKT pathway has been implicated in melanoma based primarily on the prevalence of mutations in PTEN and NRAS. To improve our understanding of the regulation and clinical significance of the PI3K-AKT pathway in...

Cite
Davies MA, Stemke-Hale K, Lin E, et al. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res. 2009;15(24):7538-7546doi: 10.1158/1078-0432.CCR-09-1985.
Davies, M. A., Stemke-Hale, K., Lin, E., Tellez, C., Deng, W., Gopal, Y. N., Woodman, S. E., Calderone, T. C., Ju, Z., Lazar, A. J., Prieto, V. G., Aldape, K., Mills, G. B., & Gershenwald, J. E. (2009). Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 15(24), 7538-7546. https://doi.org/10.1158/1078-0432.CCR-09-1985
Davies, Michael A, et al. "Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 15,24 (2009): 7538-7546. doi: https://doi.org/10.1158/1078-0432.CCR-09-1985
Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res. 2009 Dec 15;15(24):7538-7546. doi: 10.1158/1078-0432.CCR-09-1985. PMID: 19996208; PMCID: PMC2805170.
Copy Download .nbib Format: NLM
MicroRNA Processing and Human Cancer.

Journal of clinical medicine

Ohtsuka M, Ling H, Doki Y, Mori M, Calin GA.
PMID: 26308063
J Clin Med. 2015 Aug 21;4(8):1651-67. doi: 10.3390/jcm4081651.

MicroRNAs (miRNAs) are short non-coding RNAs of 20 to 25 nucleotides that regulate gene expression post-transcriptionally mainly by binding to a specific sequence of the 3' end of the untranslated region (3'UTR) of target genes. Since the first report...

Cite
Ohtsuka M, Ling H, Doki Y, et al. MicroRNA Processing and Human Cancer. J Clin Med. 2015;4(8):1651-67doi: 10.3390/jcm4081651.
Ohtsuka, M., Ling, H., Doki, Y., Mori, M., & Calin, G. A. (2015). MicroRNA Processing and Human Cancer. Journal of clinical medicine, 4(8), 1651-67. https://doi.org/10.3390/jcm4081651
Ohtsuka, Masahisa, et al. "MicroRNA Processing and Human Cancer." Journal of clinical medicine vol. 4,8 (2015): 1651-67. doi: https://doi.org/10.3390/jcm4081651
Ohtsuka M, Ling H, Doki Y, Mori M, Calin GA. MicroRNA Processing and Human Cancer. J Clin Med. 2015 Aug 21;4(8):1651-67. doi: 10.3390/jcm4081651. PMID: 26308063; PMCID: PMC4555082.
Copy Download .nbib Format: NLM
The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domain.

JAK-STAT

McMurray JS, Mandal PK, Liao WS, Klostergaard J, Robertson FM.
PMID: 24058783
JAKSTAT. 2012 Oct 01;1(4):263-347. doi: 10.4161/jkst.22682.

Herein we review our progress on the development of phosphopeptide-based prodrugs targeting the SH2 domain of STAT3 to prevent recruitment to cytokine and growth factor receptors, activation, nuclear translocation and transcription of genes involved in cancer. We developed high...

Cite
McMurray JS, Mandal PK, Liao WS, et al. The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domain. JAKSTAT. 2012;1(4):263-347doi: 10.4161/jkst.22682.
McMurray, J. S., Mandal, P. K., Liao, W. S., Klostergaard, J., & Robertson, F. M. (2012). The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domain. JAK-STAT, 1(4), 263-347. https://doi.org/10.4161/jkst.22682
McMurray, John S, et al. "The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domain." JAK-STAT vol. 1,4 (2012): 263-347. doi: https://doi.org/10.4161/jkst.22682
McMurray JS, Mandal PK, Liao WS, Klostergaard J, Robertson FM. The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domain. JAKSTAT. 2012 Oct 01;1(4):263-347. doi: 10.4161/jkst.22682. PMID: 24058783; PMCID: PMC3670284.
Copy Download .nbib Format: NLM
PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint.

Oncoimmunology

Haymaker C, Wu R, Bernatchez C, Radvanyi L.
PMID: 22934265
Oncoimmunology. 2012 Aug 01;1(5):735-738. doi: 10.4161/onci.20823.

The elevated expression of PD-1, BTLA, and other co-inhibitory molecules on T cells from cancer patients has become an accepted signature for a state called T-cell "exhaustion" that has emerged almost as dogma in the field. However, here we...

Cite
Haymaker C, Wu R, Bernatchez C, et al. PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint. Oncoimmunology. 2012;1(5):735-738doi: 10.4161/onci.20823.
Haymaker, C., Wu, R., Bernatchez, C., & Radvanyi, L. (2012). PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint. Oncoimmunology, 1(5), 735-738. https://doi.org/10.4161/onci.20823
Haymaker, Cara, et al. "PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint." Oncoimmunology vol. 1,5 (2012): 735-738. doi: https://doi.org/10.4161/onci.20823
Haymaker C, Wu R, Bernatchez C, Radvanyi L. PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint. Oncoimmunology. 2012 Aug 01;1(5):735-738. doi: 10.4161/onci.20823. PMID: 22934265; PMCID: PMC3429577.
Copy Download .nbib Format: NLM
Hodgkin Lymphoma Cells Have a Specific Long Noncoding RNA Expression Pattern.

The American journal of pathology

Anfossi S, Calin GA.
PMID: 27456130
Am J Pathol. 2016 Sep;186(9):2251-3. doi: 10.1016/j.ajpath.2016.07.002. Epub 2016 Jul 25.

This commentary highlights the article by Tayari et al that suggests studying clinical implications of long noncoding RNAs as possible diagnostic and predictive biomarkers of Hodgkin lymphoma.

Cite
Anfossi S, Calin GA. Hodgkin Lymphoma Cells Have a Specific Long Noncoding RNA Expression Pattern. Am J Pathol. 2016;186(9):2251-3doi: 10.1016/j.ajpath.2016.07.002.
Anfossi, S., & Calin, G. A. (2016). Hodgkin Lymphoma Cells Have a Specific Long Noncoding RNA Expression Pattern. The American journal of pathology, 186(9), 2251-3. https://doi.org/10.1016/j.ajpath.2016.07.002
Anfossi, Simone, and Calin, George A. "Hodgkin Lymphoma Cells Have a Specific Long Noncoding RNA Expression Pattern." The American journal of pathology vol. 186,9 (2016): 2251-3. doi: https://doi.org/10.1016/j.ajpath.2016.07.002
Anfossi S, Calin GA. Hodgkin Lymphoma Cells Have a Specific Long Noncoding RNA Expression Pattern. Am J Pathol. 2016 Sep;186(9):2251-3. doi: 10.1016/j.ajpath.2016.07.002. Epub 2016 Jul 25. PMID: 27456130; PMCID: PMC5012504.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 25 entries